The HCFC1R1 Knockout PaTu 8988t Polyclonal Cells represent a heterogeneous population of PaTu 8988t cells that have undergone CRISPR/Cas9-mediated disruption of the HCFC1R1 gene. This pooled format ensures a loss-of-function model without clonal selection, offering a polyclonal background suitable for studying gene function in a genetically diverse cell pool. The targeted disruption of HCFC1R1, a critical regulator of the HCFC1 transcriptional coactivator, enables researchers to dissect its role in transcriptional control and cell cycle progression specifically within a pancreatic adenocarcinoma context.
The PaTu 8988t cell line is a well-characterized model of human pancreatic adenocarcinoma, originally derived from a liver metastasis. This metastatic origin provides a physiologically relevant system for investigating the molecular mechanisms driving advanced pancreatic cancer. The cells retain key signaling and transcriptional programs characteristic of pancreatic tumors, making them a valuable host for gene-editing studies aimed at understanding disease progression and metastasis. The use of this cell line for HCFC1R1 knockout thus positions the model within a clinically meaningful framework for pancreatic cancer research.
HCFC1R1 functions as a modulator of the HCFC1 coactivator, which partners with E2F transcription factors to orchestrate cell cycle gene expression. It interacts with HCFC1, THAP11, SIN3A, and HDAC1 within chromatin-modifying complexes, while its activity is regulated by CDK2/Cyclin E. Downstream, it influences the HCFC1-E2F1 axis, affecting targets such as CCNE1 and CDC6. Mechanistically, HCFC1R1 acts upstream of HCFC1, which is required for E2F1-mediated transcriptional activation; knockout impairs HCFC1-dependent control of E2F target genes, altering cell cycle dynamics. The interplay with the CDK2/Cyclin E?CRb?CE2F circuit underscores its role in coordinating proliferative signals.
In PaTu 8988t cells, knockout of HCFC1R1 offers a powerful tool to examine how disruption of this regulatory node affects pancreatic adenocarcinoma cell behavior. Given that HCFC1-driven transcription is frequently dysregulated in cancer, this loss-of-function model enables investigation of the dependency of pancreatic cancer cells on the HCFC1R1?CHCFC1?CE2F pathway for sustained proliferation. Researchers can assess whether abrogation of HCFC1R1 attenuates cell cycle progression, reduces growth capacity, or sensitizes cells to therapeutic agents. This model thus holds promise for identifying vulnerabilities in the transcriptional machinery that supports pancreatic tumor maintenance.
Typical applications include quantitative analysis of E2F target gene expression via RT-qPCR, monitoring of cell cycle phases by flow cytometry, and proliferation assays such as MTT or BrdU incorporation. Co-immunoprecipitation studies can probe the physical interaction between HCFC1R1 and HCFC1, while chromatin immunoprecipitation (ChIP-qPCR) allows assessment of E2F1 occupancy at promoters of cell cycle genes. These experiments position the HCFC1R1 knockout cells as a resource for dissecting transcriptional regulatory networks in pancreatic adenocarcinoma and for screening potential drug targets. For additional details or technical support, please contact Ascent Research.
